Immuno-oncology company Imugene (ASX:IMU) has dosed the first patient in Moldova in Eastern Europe for the treatment of HER-2 positive gastric cancer.
It's an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine.
HER-Vaxx is a potentially groundbreaking cancer vaccine designed to produce an antibody response against a cancer growth signal receptor protein called HER-2 which is found on the cell surface of multiple cancers including breast and gastic cancers.
The start of the Phase 2 study is an important milestone for Imugene and the many medical professionals seeking treatments for patients with advanced HER-2 positive gastric cancer who often have very few medical options.
The Phase 1b HER-Vaxx study reported no safety or toxicity issues. All evaluable patients showed increased antibody responses.
One patient saw a complete response, five had a partial response and four recorded a stabilisation of their disease.
Shares in Imugene (ASX:IMU) Opened flat at 2 cents.